Stocks Health care CRDF
NASDAQ · Health careCardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. brought in $508K of revenue over the twelve months to June 30, 2026, down 6.8% from a year earlier. It posted a net loss of $40.1M. In fiscal 2025 capital spending exceeded operating cash flow by $38M. At June 30, 2026 it held $9.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Cardiff Oncology, Inc. does
Cardiff Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRDF.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $593K | -$45.9M | -$0.69 | -$38M |
| 2024 | $683K | -$45.4M | -$0.95 | -$37.8M |
| 2023 | $488K | -$41.4M | -$0.93 | -$31.5M |
| 2022 | $386K | -$38.7M | -$0.89 | -$34.8M |
| 2021 | $359K | -$28.3M | -$0.73 | -$23.2M |
| 2020 | $366K | -$19.3M | -$1.08 | -$16.5M |
Latest SEC filings
What Cardiff Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- August 26, 2026Additional proxy material DEFA14A
- August 26, 2026Proxy statement DEF 14A
- August 14, 2026Preliminary proxy statement PRE 14A
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 21, 2026
- July 16, 2026
- July 16, 2026
Questions about CRDF
What does Cardiff Oncology, Inc. do?
Cardiff Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRDF.
Is Cardiff Oncology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $40.1M on revenue of $508K.
How much revenue does Cardiff Oncology, Inc. make?
Over the twelve months to June 30, 2026 Cardiff Oncology, Inc. reported revenue of $508K. That is 6.8% less than a year earlier.
When did Cardiff Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 14, 2026.
Similar companies
Follow CRDF
Get an email when Cardiff Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CRDF: get an email when it filesWhere the numbers come from
Financial figures are the values Cardiff Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.